Valens (TSXV:VGW, CSE:VGW, OTCQB:VGWCF) CEO Tyler Robson joined the Investing News Network to discuss his company’s plans ahead of the legalization of cannabis extracts in Canada.

The company has secured partnerships with eight of the top 10 licensed producers in Canada, therefore establishing Valens as an essential player in the Canadian cannabis extracts space.Valens CEO Tyler Robson says that based on findings in a report entitled “The Future of Cannabis in Canada,” he believes Canadians are interested in new delivery methods for ingesting cannabis.

According to Valens CEO Tyler Robson, the company intends to capitalize on the second wave of legalization in Canada before expanding beyond its current domestic operations. Currently, Valens offers a variety of services to its clients. These services include analytical testing, product development, extraction and formulation testing. According to Valens CEO Tyler Robson, the company also plans to establish a footprint in Europe, South America and Australia.

Click on the video below to watch our interview with Valens CEO Tyler Robson

Below is a transcript of our interview with Valens CEO Tyler Robson. It has been edited for clarity and brevity.

Investing News Network: Please tell us your name, your company and its ticker symbol.

Valens CEO Tyler Robson: I’m Tyler Robson, CEO and director of Valens GroWorks. Our stock ticker is VGW on the CSE and VGWCF on the OTC.

INN: Are there any findings you would like to highlight from “The Future of Cannabis in Canada” report?

TR: Yes, there are two main things we want to highlight. Firstly, two-thirds of Canadians would like to use edibles or beverages as a different delivery system for ingesting cannabis. Secondly, men and women of all ages are spending the same amount of money on cannabis products.

INN: How is Valens preparing for the legalization of edibles and concentrates in October?

TR: The Canadian cannabis landscape is changing and we believe that a lot of people are excited for concentrates, beverages and auxiliary products. These are coming later this year, close to or on October 17. Further to that, we believe that people want different delivery systems, and we’re really trying to ramp up in our product offerings for consumers.

INN: What can you tell us about Valens’ extraction partnerships and agreements? 

TR: We have signed eight of the top 10 licensed producers in Canada for different types of extraction services, whether it’s hydrocarbon, ethanol or CO2. In addition, we also offer different levels of refinement, ranging from crude to an isolate, or in actual product development for gel caps, tinctures or vaporizer pens.

INN: What types of services do you offer your partners and clients?

TR: We offer multiple services that range from analytical testing, product development, extraction or even fee-for-service formulation testing.

INN: Could you please tell us about Valens’ domestic and global expansion plans?

TR: As the Canadian sector starts to mature, we believe we have a very strong foothold in Canada. In Canada, it’s all about execution. Since our business model is so profitable and fundamentally sound, we plan on taking it to the domestic market and the global market as well. More importantly, we plan to have a footprint in Europe, South America and eventually Australia.

This interview is sponsored by Valens GroWorks (CSE:VGW, OTCQB:VGWCF). This interview provides information which was sourced by the Investing News Network (INN) and approved by Valens GroWorks in order to help investors learn more about the company. Valens GroWorks is a client of INN. The company’s campaign fees pay for INN to create and update this interview.

INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.

The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Valens GroWorks and seek advice from a qualified investment advisor.

This interview may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, receipt of property titles, etc. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. The issuer relies upon litigation protection for forward-looking statements. Investing in companies comes with uncertainties as market values can fluctuate.

Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry

Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:

Nextleaf Comments on Financial Results from Q1 Financials

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at All dollar figures are quoted in Canadian dollars.

The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.

Keep reading... Show less

Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues

FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million

Keep reading... Show less

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

Keep reading... Show less